

 FORM PTO-1449 <u>SECOND SUPPLEMENTAL</u> <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1488.0310005/EKS/PSC	APPLICATION NO. 09/333,966
	APPLICANT YU et al.	
	FILING DATE June 16, 1999	GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

~~RECEIVED~~


NOV 26 2002

FECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
<i>L</i>	AM2	WO 97/33904	09/18/1997	WIPO			Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT	<u>35</u>	Chen, G., et al., "Induction of p53-Independent Apoptosis by Hygromycin B: Suppression by Bcl-2 and Adenovirus E1B 19-kDa Protein," <i>Exp. Cell Res.</i> 221:55-59, Academic Press, Inc. (November 1995).

100

DATE CONSIDERED 2-14-63

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449 <u>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 1488.0310005/EKS/PSC	APPLICATION NO. 09/333,966
		APPLICANT YU et al.	FILING DATE June 16, 1999
		GROUP 1646	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED

NOV 26 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

✓	AR	36 ✓	Cotter, T.G., et al., "The Induction of Apoptosis by Chemotherapeutic Agents Occurs in All Phases of the Cell Cycle," <i>Anticancer Res.</i> 12:773-780, J.G. Delinassios (1992).
✓	AS	36 ✓	Huss, R., et al., "Cyclosporine-induced apoptosis in CD4+ T lymphocytes and computer-simulated analysis: modeling a treatment scenario for HIV infection," <i>Res. Immunol.</i> 146:101-108, Elsevier (February 1995).
✓	AT	36 ✓	Van Antwerp, D.J., et al., "Inhibition of TNF-induced apoptosis by NF-κB," <i>Trends Cell Biol.</i> 8:107-111, Elsevier Science Ltd. (1998).

EXAMINER

Tor C

DATE CONSIDERED

2/14/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

NOV 26 2002

TECH CENTER 1600/2900

Page 3 of 3



FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 1488.0310005/EKS/PSC	APPLICATION NO. 09/333,966
		APPLICANT YU et al.	
		FILING DATE June 16, 1999	GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	37	Walter, D.H., et al., "Cyclosporin A Inhibits Apoptosis of Human Endothelial Cells by Preventing Release of Cytochrome C From Mitochondria," Circulation 98:1153-1157, American Heart Association, Inc. (1998).
	AS	37	Wang, E.C.Y., et al., "DR3 Regulates Negative Selection during Thymocyte Development," Mol. Cell. Biol. 21:3451-3461, American Society for Microbiology (2001).
	AT		

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.